All IGFBP-3 reagents are produced in house and quality controlled, including 8 IGFBP-3 Antibody, 2 IGFBP-3 ELISA, 26 IGFBP-3 Gene, 2 IGFBP-3 Lysate, 2 IGFBP-3 Protein, 1 IGFBP-3 qPCR. All IGFBP-3 reagents are ready to use.
Recombinant IGFBP-3 proteins are expressed by HEK293 Cells with fusion tags as N-His.
IGFBP-3antibodies are validated with different applications, which are ELISA, ELISA(Det), ELISA(Cap), IHC-P.
IGFBP-3cDNA clones are full length sequence confirmed and expression validated. There are 13 kinds of tags for each IGFBP-3 of different species, especially GFP tag, OFP tag, FLAG tag and so on. There are three kinds of vectors for choice, cloning vector, expression vector and lentivrial expression vector.
IGFBP-3ELISA Kit are quality controlled by 8 internation QC standard which guarantee every ELISA Kit with high quality.
The Insulin-like Growth Factor (IGF) signaling system plays a central role in cellular growth, differentiation and proliferation. IGFBP3 is the most abundant IGF binding protein in human serum and has been shown to be a growth inhibitory, apoptosis-inducing molecule, capable of acting via IGF-dependent and IGF-independent mechanisms. It appears to function both by cell cycle blockade and the induction of apoptosis. IGFBP3 can be transported to the nucleus by an importin beta mediated mechanism, where it has been shown to interact with the retinoid X receptor alpha and possibly other nuclear elements. IGFBP3 antiproliferative signalling appears to require an active transforming growth factor beta (TGF-beta) signalling pathway, and IGFBP3 stimulates phosphorylation of the TGF-beta signalling intermediates Smad2 and Smad3. IGFBP3 has IGF-independent roles in inhibiting cell proliferation in cancer cell lines. Nuclear transcription factor, retinoid X receptor (RXR)-alpha, and IGFBP3 functionally interact to reduce prostate tumor growth and prostate-specific antigen in vivo. Several clinical studies have proposed that individuals with IGFBP3 levels in the upper range of normal may have a decreased risk for certain common cancers. This includes evidence of a protective effect against breast cancer, prostate cancer, colorectal cancer, and lung cancer. Moreover, IGFBP3 inhibits insulin-stimulated glucose uptake into adipocytes independent of IGF.